Personalized genomics will only be useful for monitoring the prognosis of patients with cancer when it becomes much more cost-effective and quicker to apply.
A recent study brings this closer to reality with the development of plasma-seq, a rapid, low-cost method that sequences the circulating DNA present in the peripheral blood of patients with cancer. The power of this technique is demonstrated with the examination of tumor genomes from patients with prostate cancer.
Written by:
Farris C, Trimarchi JM. Are you the author?
Department of Genetics, Development and Cell Biology, 2114 Molecular Biology, Iowa State University, Ames, IA 50011, USA.
Reference: Genome Med. 2013 Apr 29;5(4):35.
PubMed Abstract
PMID: 23673197
